Latest News
ISCT Asia 2026
Ascensus Therapeutics was invited to present the
novel LICRA approach at the ISCT Asia 2026 conference in Singapore.
2025 ISCT International
Ascensus Therpeutics was invited to present the Rescue Protein based
cell therapy platform at the 2025 ISCT International Conference in New
Orleans.
Completion of First-Intrapatient dose escalation
Ascensus Therapeutics announces the successful completion of First
Intrapatient dose escalation in ATX-301 clinical trial for advanced
adenocarcinomas
More Info Coming Soon
BioCentury Grand Rounds
Ascensus Therapeutics was invited to present at the BioCentury Grand Rounds meeting in Nashville, TN.
Sachs Oncology Innovation Forum
Ascensus Therapeutics was invited to present the novel approach and recent progress developed at the 11th Annual Oncology Innovation Forum.
Clearance to Initiate First-in-
Human Clinical Trial
Ascensus Therapeutics has received regulatory clearance to begin its first-in-human Phase I/IIa clinical trial of its lead cell therapy for adenocarcinoma. The study will evaluate safety and early biological activity in patients with advanced disease.